These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24630925)

  • 1. Comment on Numao et al.: Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Picillo M; Barone P; Erro R; Spina E; Pellecchia MT
    Parkinsonism Relat Disord; 2014 Jun; 20(6):680-1. PubMed ID: 24630925
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' reply to the comments of Picillo et al. regarding "Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy".
    Suzuki K; Numao A; Miyamoto M; Miyamoto T; Hirata K
    Parkinsonism Relat Disord; 2014 Jun; 20(6):682-3. PubMed ID: 24709085
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Numao A; Suzuki K; Miyamoto M; Miyamoto T; Hirata K
    Parkinsonism Relat Disord; 2014 Feb; 20(2):212-6. PubMed ID: 24280021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum uric acid levels in progressive supranuclear palsy.
    Oropesa-Ruiz JM; Huertas-Fernández I; Jesús S; Cáceres-Redondo MT; Vargas-Gonzalez L; Carrillo F; Carballo M; Gómez-Garre P; Mir P
    Mov Disord; 2016 Mar; 31(3):402-5. PubMed ID: 26686202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum metabolomics study in a group of Parkinson's disease patients from northern India.
    Nagesh Babu G; Gupta M; Paliwal VK; Singh S; Chatterji T; Roy R
    Clin Chim Acta; 2018 May; 480():214-219. PubMed ID: 29474999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy.
    Mori A; Ishikawa KI; Saiki S; Hatano T; Oji Y; Okuzumi A; Fujimaki M; Koinuma T; Ueno SI; Imamichi Y; Hattori N
    PLoS One; 2019; 14(9):e0223113. PubMed ID: 31560709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The circulating level of leptin and blood pressure in patients with multiple system atrophy.
    Ozawa T; Tokunaga J; Arakawa M; Ishikawa A; Takeuchi R; Yokoseki A; Sone H; Nishizawa M
    J Neurol Sci; 2014 Dec; 347(1-2):349-51. PubMed ID: 25304054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
    Messina D; Cerasa A; Condino F; Arabia G; Novellino F; Nicoletti G; Salsone M; Morelli M; Lanza PL; Quattrone A
    Parkinsonism Relat Disord; 2011 Mar; 17(3):172-6. PubMed ID: 21236720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.
    Brown RG; Lacomblez L; Landwehrmeyer BG; Bak T; Uttner I; Dubois B; Agid Y; Ludolph A; Bensimon G; Payan C; Leigh NP;
    Brain; 2010 Aug; 133(Pt 8):2382-93. PubMed ID: 20576697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of the superior cerebellar peduncle for differential diagnosis of progressive supranuclear palsy: A meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2017 Jul; 378():153-157. PubMed ID: 28566154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease.
    Pellecchia MT; Pivonello R; Colao A; Barone P
    Clin Med Res; 2006 Dec; 4(4):322-5. PubMed ID: 17210980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Antoni S; Ferger D; Reichmann H; Wilhelm H; Berg D; Ziemssen T
    Mov Disord; 2007 Oct; 22(14):2123-6. PubMed ID: 17853484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies.
    Constantinescu R; Andreasson U; Holmberg B; Zetterberg H
    Acta Neurol Scand; 2013 Feb; 127(2):e8-12. PubMed ID: 22998191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease.
    Kass-Iliyya L; Kobylecki C; McDonald KR; Gerhard A; Silverdale MA
    Brain Behav; 2015 May; 5(5):e00320. PubMed ID: 25874161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and cognitive correlations of regional gray matter atrophy in progressive supranuclear palsy.
    Giordano A; Tessitore A; Corbo D; Cirillo G; de Micco R; Russo A; Liguori S; Cirillo M; Esposito F; Tedeschi G
    Parkinsonism Relat Disord; 2013 Jun; 19(6):590-4. PubMed ID: 23477861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy.
    Wenning GK; Colosimo C
    Rev Neurol (Paris); 2010 Oct; 166(10):829-33. PubMed ID: 20813385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Tong J; Fitzmaurice PS; Ang LC; Furukawa Y; Guttman M; Kish SJ
    Ann Neurol; 2004 Jan; 55(1):125-9. PubMed ID: 14705122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.